Like your local educational TV or radio station, our Forum relies on help from visitors like you. The grant funding we receive does not fully cover our costs; please consider making a recurring monthly contribution or a one-time donation.
Click
here for more information about the following ads
Current Postings on This Page (1):
I am interested in research info on the connection of CYP3A4 enzyme in the metabolism of everolimus and other DES drugs on body. And, consequences. I had 3 Xience DES stents (40 mm) and 2 LAD/D2 stents (Synergy) in 2017 at Stanford Medical Center. Excellent IC care but so lacking in thinking "out of the box". They don't even know what CYP3A4 is and haven't a clue whether or not it would impact metaoblism and create problems beyond cardio issues. Also, the addition of Plavix - same questions. In Dec 2017, 6 mos after all of the insertions and Plavix, I started terrible MAST cell activation. Nothing in journals about this subject. Any information? Relevant or not? Jeanette Y., patient, San Francisco, California area, USA, August 5, 2019